The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametinib to target atypical teratoid/rhabdoid tumors-MedSci.cn - 梅斯（MedSci）

The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametinib to target atypical teratoid/rhabdoid tumors

Malebranche, KJ; Findlay, T; Geethadevi, A; Eberhart, C; Raabe, E; Rubens, J

CANCER RESEARCH, 2023; 83 (7):

科室
- - 订阅+
  - 更多科室
工具
服务